Pharmacotherapeutic Management of Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices

被引：26
作者：
Sieg, Adam C. [1 ]
Moretz, Jeremy D. [2 ]
Horn, Edward [3 ]
Jennings, Douglas L. [4 ]
机构：
[1] Univ Kentucky, Dept Pharm, Lexington, KY USA
[2] Vanderbilt Univ, Med Ctr, Dept Pharm, Nashville, TN USA
[3] Allegheny Gen Hosp, Dept Pharm, Pittsburgh, PA 15212 USA
[4] Columbia Univ, Med Ctr, Dept Pharm, New York Presbyterian Hosp, New York, NY USA
来源：
PHARMACOTHERAPY | 2017年 / 37卷 / 11期
关键词：
gastrointestinal bleeding; octreotide; thalidomide; anticoagulation; continuous-flow left ventricular assist device; VON-WILLEBRAND-SYNDROME; ARTERIOVENOUS-MALFORMATIONS; FACTOR DEGRADATION; RISK; OCTREOTIDE; ANGIODYSPLASIA; INHIBITORS; DISEASE; SAFETY; PUMP;
D O I：
10.1002/phar.2016
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Continuous-flow left ventricular assist devices (CF-LVADs) have become an integral component of the management in patients with advanced heart failure, serving as destination therapy or as a bridge to heart transplantation. Despite significant advances in the design and longevity of the device, the ongoing risk for bleeding remains a significant concern. The genesis of gastrointestinal bleeding (GIB) in patients with CF-LVADs is likely multifactorial and may include components of acquired von Willebrand disease, angiodysplasia, and gastrointestinal arteriovenous malformations, as well as additional risk factors such as history of GIB and increased age. Several pharmacotherapy options have been used, but the data surrounding their overall efficacy remain sparse. The necessity for larger prospective studies is essential to further advance the management of this devastating complication. Within this review, we discuss the known pathophysiologic process of CF-LVAD-related GIB and highlight the therapeutic options discussed within the literature. In addition, we discuss potential therapeutic options based on mechanisms of action as they correlate to known pathophysiologic processes of CF-LVAD-related GIB. Finally, we provide recommendations for constructing drug therapy regimens in patients with CF-LVADs who develop GIB.
引用
收藏
页码：1432 / 1448
页数：17
相关论文
共 79 条
[1]   Use of an Intrapericardial, Continuous-Flow, Centrifugal Pump in Patients Awaiting Heart Transplantation [J].
Aaronson, Keith D. ;
Slaughter, Mark S. ;
Miller, Leslie W. ;
McGee, Edwin C. ;
Cotts, William G. ;
Acker, Michael A. ;
Jessup, Mariell L. ;
Gregoric, Igor D. ;
Loyalka, Pranav ;
Frazier, O. H. ;
Jeevanandam, Valluvan ;
Anderson, Allen S. ;
Kormos, Robert L. ;
Teuteberg, Jeffrey J. ;
Levy, Wayne C. ;
Naftel, David C. ;
Bittman, Richard M. ;
Pagani, Francis D. ;
Hathaway, David R. ;
Boyce, Steven W. .
CIRCULATION, 2012, 125 (25) :3191-+
[2]   Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN) [J].
Abshire, T. C. ;
Federici, A. B. ;
Alvarez, M. T. ;
Bowen, J. ;
Carcao, M. D. ;
Gill, J. Cox ;
Key, N. S. ;
Kouides, P. A. ;
Kurnik, K. ;
Lail, A. E. ;
Leebeek, F. W. G. ;
Makris, M. ;
Mannucci, P. M. ;
Winikoff, R. ;
Berntorp, E. .
HAEMOPHILIA, 2013, 19 (01) :76-81
[3]   Incidence and Management of Gastrointestinal Bleeding With Continuous Flow Assist Devices [J].
Aggarwal, Ashim ;
Pant, Rojina ;
Kumar, Shivani ;
Sharma, Priya ;
Gallagher, Colleen ;
Tatooles, Antone J. ;
Pappas, Pat S. ;
Bhat, Geetha .
ANNALS OF THORACIC SURGERY, 2012, 93 (05) :1534-1540
[4]   Von Willebrand disease, angiodysplasia and atorvastatin [J].
Alikhan, Raza ;
Keeling, David .
BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (01) :159-160
[5]   EFFECTS OF DESMOPRESSIN ACETATE ON PLATELET-AGGREGATION, VONWILLEBRAND-FACTOR, AND BLOOD-LOSS AFTER CARDIAC-SURGERY WITH EXTRACORPOREAL-CIRCULATION [J].
ANDERSSON, TLG ;
SOLEM, JO ;
TENGBORN, L ;
VINGE, E .
CIRCULATION, 1990, 81 (03) :872-878
[6]  
[Anonymous], 2016, SANDOSTATIN LAR DEPO
[7]  
[Anonymous], 2016, THAL THAL PROD MON
[8]  
[Anonymous], 2012, SANDOSTATIN OCTREOTI
[9]   Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding [J].
Bartoli, Carlo R. ;
Kang, Jooeun ;
Restle, David J. ;
Zhang, David M. ;
Shabahang, Cameron ;
Acker, Michael A. ;
Atluri, Pavan .
JACC-HEART FAILURE, 2015, 3 (11) :860-869
[10]   Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: Mechanical demolition and enzymatic cleavage [J].
Bartoli, Carlo R. ;
Restle, David J. ;
Zhang, David M. ;
Acker, Michael A. ;
Atluri, Pavan .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2015, 149 (01) :281-289
12345678